Selective Smurf1 E3 ligase inhibitors that prevent transthiolation

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• Smurf1 (SMAD ubiquitination regulatory factor 1) is a HECT E3 ligase implicated in osteoporosis due to genetic microduplication in patients.
• Smurf1 knockout mice exhibit increased bone density, highlighting Smurf1 as a viable therapeutic target for osteoporosis.

Approach:

• Discovery, synthesis, and biochemical characterization of novel, highly selective Smurf1 inhibitors.
• Assessed inhibitor potency against the catalytic HECT domain of Smurf1 (IC50 of 500 nM).
• Evaluated selectivity against the highly homologous Smurf2 ligase (80% sequence identity).

Key Points:

• Smurf1 inhibitors specifically target the HECT domain, preventing the trans-thiolation step involving E2∼Ub thioesters.
• Compounds demonstrate high selectivity for Smurf1 over Smurf2.
• Preliminary data suggest the C-lobe of Smurf1 is not essential for the observed inhibitor selectivity.

Conclusions:

• Developed highly selective Smurf1 inhibitors with potential therapeutic applications for osteoporosis.
• Inhibitors function by disrupting the E3 ligase catalytic mechanism at the trans-thiolation step.
• Further studies are warranted to explore the structural basis of Smurf1 inhibitor selectivity.